The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Diffuse large B-cell lymphoma (DLBCL).

Target Audience
This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies. 

Learning Objectives
Upon completion of this event, participants should be able to:

• Explain the mechanism of action of novel bispecific antibody therapies vs other anticancer agents and the role of bispecific antibodies in the treatment of DLBCL
• Design treatment strategies for the use of bispecific antibodies in R/R DLBCL, based on current indications, consensus guidelines, recent key safety and efficacy data, and patient and disease factors
• Assess patients for eligibility for ongoing clinical trials and for barriers to and disparities in care that may impact outcomes
• Apply recommendations to mitigate and manage adverse events associated with bispecific antibody treatment in patients with DLBCL

---

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Goal Statement
This activity aims to improve the knowledge, confidence, and skills of APPs who care for patients with CLL/SLL on the latest updates in guideline-directed evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes.

Target Audience
This activity is intended for APPs and other healthcare professionals caring for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Learning Objectives
Upon completion of this event, participants should be able to:

• Explain the differences between targeted agents for CLL/SLL based on their mechanisms of action, efficacy, and adverse event profiles to enhance patient understanding.
• Assess and manage individualized treatment plans for newly diagnosed or relapsed/refractory CLL/SLL, considering prognostic factors, comorbidities, treatment duration, and toxicity profiles.
• Implement evidence-based strategies to identify, monitor, and manage adverse events associated with CLL/SLL therapies.
• Utilize effective communication techniques to engage patients in their care, focusing on recognizing and addressing adverse events, managing drug interactions, and promoting adherence to treatment.

---

The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with breast cancer who are receiving or are eligible for CDK4/6 inhibitor therapy.

Target Audience
This activity is intended for community nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who care for patients treated with CDK 4/6 inhibitor therapies.

Learning Objectives
Upon completion of this event, participants should be able to:

• Effectively mitigate and manage toxicities associated with CDK4/6 inhibitor therapy for patients with HR+/HER2- breast cancer, including recommended dose modification strategies
• Implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in patients with HR+/HER2- breast cancer
• Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy in patients with HR+/HER2- breast cancer

---

Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with breast cancer.

Target Audience
This activity is intended for community nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who care for patients with breast cancer. 

Learning Objectives
Upon completion of this event, participants should be able to:

• Analyze clinical evidence supporting the use of ADCs in metastatic breast cancer
• Explain the structural, mechanistic, and unique characteristics of ADCs that contribute to differing toxicities and adverse event profiles
• Identify strategies for managing common and serious toxicities to effectively monitor and proactively identify signs and symptoms of serious adverse events
• Apply knowledge of ADCs, clinical evidence, and guidelines to real-world patient case scenarios

---

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with B-cell lymphomas who are receiving or are eligible for BTK inhibitor therapy. 

Target Audience
This activity is intended for nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lymphoma.

Learning Objectives
Upon completion of this event, participants should be able to:

• Describe how adverse event profiles and patient-specific factors influence the selection of BTK inhibitors in managing B-cell malignancies
• Discuss the role of biomarker-driven testing in informing BTK inhibitor therapy selection and guiding risk mitigation strategies
• Identify common patient-reported barriers to BTK inhibitor adherence and strategies—including patient education and digital health tools—to improve treatment continuity
• Explain key eligibility criteria for clinical trials investigating novel BTK inhibitors to support patient counseling and trial referral decisions